News & Updates

Show Multimedia Only

First-line therapies for advanced NSCLC improve survival, QoL

16 Oct 2023

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

16 Oct 2023

Behavioural interventions improve screening colonoscopy uptake

16 Oct 2023 by

Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

16 Oct 2023

Social deprivation tied to higher glaucoma risk

16 Oct 2023

Personal poverty, as defined by not driving a personal vehicle to the appointment, and neighbourhood-level poverty appear to contribute to higher rates of screening positive for glaucoma or suspected glaucoma, suggests a study.

16 Oct 2023

Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients

16 Oct 2023 by

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.

16 Oct 2023

Physical activity boosts functional performance in MM

16 Oct 2023 by

Exercises that include walking and resistance training are effective interventions that improve frailty in patients with multiple myeloma (MM) who are receiving systemic treatment, according to a new study.

16 Oct 2023

HIV treatment discontinuation less frequent with B/F/TAF than DTG/3TC

16 Oct 2023 by

In a real-world cohort, virologically suppressed HIV patients who switched from a prior regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were less likely to discontinue their regimen than those who switched to dolutegravir/lamivudine (DTG/3TC).

16 Oct 2023

RSV vaccine effective across two seasons

16 Oct 2023 by

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.

16 Oct 2023